Cargando…
Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation
Microglia are resident macrophages in the central nervous system that are involved in immune responses driven by Toll-like receptors (TLRs). Microglia-mediated inflammation can lead to central nervous system disorders, and more than one TLR might be involved in these pathological processes. The cyst...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016010/ https://www.ncbi.nlm.nih.gov/pubmed/35066760 http://dx.doi.org/10.1007/s12035-021-02694-2 |
_version_ | 1784688436410580992 |
---|---|
author | Pišlar, Anja Nedeljković, Biljana Božić Perić, Mina Jakoš, Tanja Zidar, Nace Kos, Janko |
author_facet | Pišlar, Anja Nedeljković, Biljana Božić Perić, Mina Jakoš, Tanja Zidar, Nace Kos, Janko |
author_sort | Pišlar, Anja |
collection | PubMed |
description | Microglia are resident macrophages in the central nervous system that are involved in immune responses driven by Toll-like receptors (TLRs). Microglia-mediated inflammation can lead to central nervous system disorders, and more than one TLR might be involved in these pathological processes. The cysteine peptidase cathepsin X has been recognized as a pathogenic factor for inflammation-induced neurodegeneration. Here, we hypothesized that simultaneous TLR3 and TLR4 activation induces synergized microglia responses and that these phenotype changes affect cathepsin X expression and activity. Murine microglia BV2 cells and primary murine microglia were exposed to the TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)) and the TLR4 ligand lipopolysaccharide (LPS), individually and simultaneously. TLR3 and TLR4 co-activation resulted in increased inflammatory responses compared to individual TLR activation, where poly(I:C) and LPS induced distinct patterns of proinflammatory factors together with different patterns of cathepsin X expression and activity. TLR co-activation decreased intracellular cathepsin X activity and increased cathepsin X localization at the plasma membrane with concomitant increased extracellular cathepsin X protein levels and activity. Inhibition of cathepsin X in BV2 cells by AMS36, cathepsin X inhibitor, significantly reduced the poly(I:C)- and LPS-induced production of proinflammatory cytokines as well as apoptosis. Additionally, inhibiting the TLR3 and TLR4 common signaling pathway, PI3K, with LY294002 reduced the inflammatory responses of the poly(I:C)- and LPS-activated microglia and recovered cathepsin X activity. We here provide evidence that microglial cathepsin X strengthens microglia activation and leads to subsequent inflammation-induced neurodegeneration. As such, cathepsin X represents a therapeutic target for treating neurodegenerative diseases related to excess inflammation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-021-02694-2. |
format | Online Article Text |
id | pubmed-9016010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90160102022-05-02 Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation Pišlar, Anja Nedeljković, Biljana Božić Perić, Mina Jakoš, Tanja Zidar, Nace Kos, Janko Mol Neurobiol Article Microglia are resident macrophages in the central nervous system that are involved in immune responses driven by Toll-like receptors (TLRs). Microglia-mediated inflammation can lead to central nervous system disorders, and more than one TLR might be involved in these pathological processes. The cysteine peptidase cathepsin X has been recognized as a pathogenic factor for inflammation-induced neurodegeneration. Here, we hypothesized that simultaneous TLR3 and TLR4 activation induces synergized microglia responses and that these phenotype changes affect cathepsin X expression and activity. Murine microglia BV2 cells and primary murine microglia were exposed to the TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)) and the TLR4 ligand lipopolysaccharide (LPS), individually and simultaneously. TLR3 and TLR4 co-activation resulted in increased inflammatory responses compared to individual TLR activation, where poly(I:C) and LPS induced distinct patterns of proinflammatory factors together with different patterns of cathepsin X expression and activity. TLR co-activation decreased intracellular cathepsin X activity and increased cathepsin X localization at the plasma membrane with concomitant increased extracellular cathepsin X protein levels and activity. Inhibition of cathepsin X in BV2 cells by AMS36, cathepsin X inhibitor, significantly reduced the poly(I:C)- and LPS-induced production of proinflammatory cytokines as well as apoptosis. Additionally, inhibiting the TLR3 and TLR4 common signaling pathway, PI3K, with LY294002 reduced the inflammatory responses of the poly(I:C)- and LPS-activated microglia and recovered cathepsin X activity. We here provide evidence that microglial cathepsin X strengthens microglia activation and leads to subsequent inflammation-induced neurodegeneration. As such, cathepsin X represents a therapeutic target for treating neurodegenerative diseases related to excess inflammation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-021-02694-2. Springer US 2022-01-23 2022 /pmc/articles/PMC9016010/ /pubmed/35066760 http://dx.doi.org/10.1007/s12035-021-02694-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pišlar, Anja Nedeljković, Biljana Božić Perić, Mina Jakoš, Tanja Zidar, Nace Kos, Janko Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title | Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title_full | Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title_fullStr | Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title_full_unstemmed | Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title_short | Cysteine Peptidase Cathepsin X as a Therapeutic Target for Simultaneous TLR3/4-mediated Microglia Activation |
title_sort | cysteine peptidase cathepsin x as a therapeutic target for simultaneous tlr3/4-mediated microglia activation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016010/ https://www.ncbi.nlm.nih.gov/pubmed/35066760 http://dx.doi.org/10.1007/s12035-021-02694-2 |
work_keys_str_mv | AT pislaranja cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation AT nedeljkovicbiljanabozic cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation AT pericmina cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation AT jakostanja cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation AT zidarnace cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation AT kosjanko cysteinepeptidasecathepsinxasatherapeutictargetforsimultaneoustlr34mediatedmicrogliaactivation |